However, the results that we present support the hypothesis that dual blockade of G9A/EZH2 histone methyltransferases modulates the tumor immune microenvironment within the peritoneal cavity, confers a survival benefit in an aggressive murine model of HGSC and warrants further investigation towards clinical development. The gene discussed is EZH2; the disease is neoplasm.